Corrigendum

Split Viewer

J Rheum Dis 2024; 31(4): 263-263

Published online October 1, 2024

© Korean College of Rheumatology

Corrigendum: Treatment sequence after initiating biologic therapy for patients with rheumatoid arthritis in Korea: a nationwide retrospective cohort study

Min Jung Kim, M.D.1, Jun Won Park, M.D.2, Sun-Kyung Lee, Ph.D.1, Yumi Jang, MPH1 , Soyoung Kim, MPH3, Matthias Stoelzel, Ph.D.4, Jonathan Lumen Chua, Ph.D.5, Kichul Shin, M.D., Ph.D.1

1Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, 3Astellas Pharma Singapore Pte. Ltd, Singapore, Singapore, 4Astellas Pharma Europe B.V., Leiden, The Netherlands, 5IQVIA Asia Pacific, Singapore, Singapore

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

J Rheum Dis 2023;30(1):26-35

https://doi.org/10.4078/jrd.22.0024

We discovered that one of the authors’ ORCID was incorrectly listed and would like to correct it.

The corrected version should be as follows:

Before:

Yumi Jang, https://orcid.org/0000-0002-0626-0458

After:

Yumi Jang, https://orcid.org/0009-0009-8762-8450

We sincerely apologize for any confusion that we may have caused.

Article

Corrigendum

J Rheum Dis 2024; 31(4): 263-263

Published online October 1, 2024 https://doi.org/10.4078/jrd.22.0024C

Copyright © Korean College of Rheumatology.

Corrigendum: Treatment sequence after initiating biologic therapy for patients with rheumatoid arthritis in Korea: a nationwide retrospective cohort study

Min Jung Kim, M.D.1, Jun Won Park, M.D.2, Sun-Kyung Lee, Ph.D.1, Yumi Jang, MPH1 , Soyoung Kim, MPH3, Matthias Stoelzel, Ph.D.4, Jonathan Lumen Chua, Ph.D.5, Kichul Shin, M.D., Ph.D.1

1Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, 3Astellas Pharma Singapore Pte. Ltd, Singapore, Singapore, 4Astellas Pharma Europe B.V., Leiden, The Netherlands, 5IQVIA Asia Pacific, Singapore, Singapore

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Body

J Rheum Dis 2023;30(1):26-35

https://doi.org/10.4078/jrd.22.0024

We discovered that one of the authors’ ORCID was incorrectly listed and would like to correct it.

The corrected version should be as follows:

Before:

Yumi Jang, https://orcid.org/0000-0002-0626-0458

After:

Yumi Jang, https://orcid.org/0009-0009-8762-8450

We sincerely apologize for any confusion that we may have caused.

JRD
Oct 01, 2024 Vol.31 No.4, pp. 191~263
COVER PICTURE
Ancestry-driven pathways for SLE-risk SNP-associated genes. The ancestry-driven key signaling pathways in Asians, Europeans, and African Americans were analyzed by enrichr (https://maayanlab.cloud/Enrichr/#libraries) using non-HLA SNP-associated genes. SLE: systemic lupus erythematosus, SNP: single-nucleotide polymorphism, JAK–STAT: janus kinase–signal transducers and activators of transcription, IFN: interferon gamma. (J Rheum Dis 2024;31:200-211)

Stats or Metrics

Share this article on

  • line

Journal of Rheumatic Diseases

pISSN 2093-940X
eISSN 2233-4718
qr-code Download